Robert S. Wiesenthal - 29 Aug 2025 Form 4 Insider Report for Strata Critical Medical, Inc. (BLDE)

Reporting relationship: Director
Issuer ticker: BLDE
Reported as of: 29 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Sep 2025, 20:43:59 UTC
Prior SEC filing: 07 Aug 2025
Next SEC filing: 01 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Melissa M. Tomkiel, Attorney-in-fact for Robert S. Wiesenthal

Key filing fact

Robert S. Wiesenthal filed Form 4 for Strata Critical Medical, Inc. (BLDE) on 03 Sep 2025.

Key facts

This page summarizes Robert S. Wiesenthal's Form 4 filing for Strata Critical Medical, Inc. (BLDE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Sep 2025, 20:43.

Change

Previous filing in this sequence was filed on 07 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001211785 Primary reporting owner

WIESENTHAL ROBERT S

Relationship: Director
Address: C/O STRATA CRITICAL MEDICAL, INC., 31 HUDSON YARDS, 14TH FLOOR, NEW YORK
Signature: /s/ Melissa M. Tomkiel, Attorney-in-fact for Robert S. Wiesenthal
Signature date: 03 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SRTA transaction

Class A common stock, $0.0001 par value per share

Award

Transaction value: $0
Shares: +40,607
Change %: +0.78%
Price: $0.000000
Shares after: 5,275,662
Date: 29 Aug 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2026 Annual Meeting of Stockholders.

Footnote F2

Effective as of September 2, 2025, the terms of 886,886 unvested RSUs granted to the Reporting Person by the Issuer on November 9, 2022 and originally reported by the Reporting Person in Table I of a Form 4 filed on November 14, 2022 and 33,591 unvested RSUs granted to the Reporting Person by the Issuer on December 16, 2021 and originally reported by the Reporting Person in Table I of a Form 4 on December 20, 2021, were amended by the Issuer's board of directors to make them subject to an additional performance-related vesting condition. As a result of such amendment, the shares of the Issuer's common stock underlying such unvested RSUs will no longer be included in the securities beneficially owned by the Reporting Person as reflected in column 5 of Table I. Upon satisfaction of the relevant performance-related vesting condition, the Reporting Person will again report the acquisition of such shares on a Form 4.